Amneal Pharmaceuticals Executive Compensation (FY25)
AMRX · Executive and director compensation, fiscal 2025 only
The Amneal Pharmaceuticals brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of September 7, 2026Latest filing (8-K): May 7, 2026
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
211 figures on this page: 204 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
Frequently asked questions
Answers drawn from the data on this page.
Who is Amneal Pharmaceuticals' chief executive and what were they paid?
Chirag Patel, Co-Chief Executive Officer and President, received $8,691,745 in total compensation for fiscal 2025.
What was Amneal Pharmaceuticals' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 99.0% of votes cast including abstentions in favor at the meeting held May 6, 2026.
Which companies are in Amneal Pharmaceuticals' peer group?
The disclosed peer group includes Alkermes plc, Amphastar Pharmaceuticals, Inc., ANI Pharmaceuticals, Inc., Emergent BioSolutions Inc. and Jazz Pharmaceuticals plc, among others.
What is Amneal Pharmaceuticals' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 679:1, against median employee compensation of $12,853.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Chirag Patel Co-Chief Executive Officer and President | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Anastasios Konidaris EVP & Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Andrew Boyer EVP, Chief Commercial Officer - Generics | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Jason Daly EVP, Chief Legal Officer & Secretary | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Nikita Shah EVP, Chief Human Resources Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Anastasios Konidaris | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Anastasios Konidaris | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Andrew Boyer | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Andrew Boyer | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Chintu Patel | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Chintu Patel | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Chirag Patel | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Chirag Patel | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Jason Daly | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Jason Daly | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Nikita Shah | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Nikita Shah | RSU | ◇ | — | — | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Chirag Patel | PSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Jason Daly | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Nikita Shah | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Andrew Boyer | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Anastasios Konidaris | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Chirag Patel
Co-Chief Executive Officer and President · Severance agreement
| Clawback | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Emily Peterson Alva | ◇ | ◇ | — | — | — | ◇ | ◇ |
Paul Meister Board chair | ◇ | ◇ | — | — | — | — | ◇ |
John Kiely | ◇ | ◇ | — | — | — | ◇ | ◇ |
Jeff George | ◇ | ◇ | — | — | — | ◇ | ◇ |
Ted Nark | ◇ | ◇ | — | — | — | ◇ | ◇ |
J. Kevin Buchi | ◇ | ◇ | — | — | — | — | ◇ |
Shlomo Yanai | ◇ | ◇ | — | — | — | ◇ | ◇ |
Gautam Patel | ◇ | ◇ | — | — | — | ◇ | ◇ |
Chirag Patel, Chintu Patel and Deb Autor served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Alkermes plc ALKS
- Amphastar Pharmaceuticals, Inc. AMPH
- ANI Pharmaceuticals, Inc. ANIP
- Emergent BioSolutions Inc. EBS
- Jazz Pharmaceuticals plc JAZZ
- Neurocrine Biosciences, Inc. NBIX
- Pacira BioSciences, Inc. PCRX
- Perrigo Company plc PRGO
- Prestige Consumer Healthcare Inc. PBH
- Supernus Pharmaceuticals, Inc. SUPN
- United Therapeutics Corporation UTHR
- Viatris Inc. VTRS
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 6, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 6, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 2, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 9, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | May 9, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | May 5, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | May 5, 2020 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Amneal Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Amneal Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
211 figures on this page: 204 cited to the filing that reported them, 7 calculated from figures it prints.
204 cited to the filing
7 calculated from the filing
Documents cited
- 0001628280-26-032137
- 0001308179-26-000143CEO Pay Ratio · Director Compensation · Grants of Plan Based Awards in 2025 · Outstanding Equity Awards at December 31, 2025 · and 1 more section
- 0001723128-25-000024
- 0001628280-24-021107
- 0001723128-23-000023
- 0001723128-22-000019
- 0001193125-21-156284
- 0001723128-20-000013
- 0001193125-20-136972
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Amneal Pharmaceuticals executive compensation, FY2025.” https://intel.velarion.ai/comp/AMRX (accessed 2026).
Short form: data: Velarion
The Amneal Pharmaceuticals brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Amneal Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Amneal Pharmaceuticals discloses
The companies named in AMRX's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}